Cimantin Dosage & Drug Information

Concise Prescribing Info Bahasa Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Concise Prescribing Info

Contents

Memantine HCl

Indications/Uses

Moderate to severe Alzheimer's disease.

Click to view Cimantin detailed prescribing information

Dosage/Direction for Use

Adult Dose titration: Max daily dose: 20 mg. In order to reduce undesirable effects, maintenance dose is achieved by upward titration of 5 mg wkly over the 1st 3 wk as follows: Wk 1 (day 1-7): 5 mg daily; wk 2 (day 8-14): 10 mg daily; wk 3 (day 15-21): 15 mg daily; wk 4 & maintenance: 20 mg daily. Elderly >65 yr 20 mg daily. Severe renal impairment (CrCl 5-29 mL/min) 10 mg daily. Moderate renal impairment (CrCl 30-49 mL/min) 10 mg daily, increased up to 20 mg daily if tolerated well after at least 7 days.

Click to view Cimantin detailed prescribing information

Overdosage

View Cimantin overdosage for action to be taken in the event of an overdose.

Administration

May be taken with or without food.

Contraindications

Hypersensitivity. Concomitant use of medications containing NMDA-antagonist dextromethorphan.

Click to view Cimantin detailed prescribing information

Special Precautions

Patients w/ epilepsy; recent MI, uncompensated CHF (NYHA III-IV) & uncontrolled HTN. Careful monitoring of patients w/ factors that may elevate urine pH eg, drastic changes in diet, ingestion of alkalising gastric buffers, renal tubular acidosis, severe UTI w/ Proteus bacteria. Not recommended in patients w/ severe hepatic impairment. Minor to moderate influence on the ability to drive & use machines. Should not be used during pregnancy. Women taking memantine should not breast-feed. Childn & adolescents <18 yr.

Click to view Cimantin detailed prescribing information

Use In Pregnancy & Lactation

Click to view Cimantin detailed prescribing information

Adverse Reactions

Drug hypersensitivity; somnolence; dizziness, balance disorders; HTN; dyspnoea; constipation; elevated LFT; headache.

Click to view Cimantin detailed prescribing information

Drug Interactions

Enhanced effects of L-dopa, dopaminergic agonists & anticholinergics. Reduced effects of barbiturates & neuroleptics. Modified effects of antispasmodic agents, dantrolene or baclofen. Avoid concomitant use w/ NMDA antagonists eg, amantadine, ketamine or dextromethorphan. Possible risk w/ phenytoin. Increased plasma levels w/ cimetidine, ranitidine, procainamide, quinidine, quinine & nicotine. Possible reduction of hydrochlorothiazide serum level. Increased INR w/ warfarin. Consider possible drug interaction w/ benzodiazepines & antidepressants.

Click to view Cimantin detailed prescribing information

Caution For Usage

For caution against possible variation of physical aspect of medicine... Click to view Cimantin detailed prescribing information

Storage

View Cimantin storage conditions for details to ensure optimal shelf-life.

Description

View Cimantin description for details of the chemical structure and excipients (inactive components).

Action

View Cimantin mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Neurodegenerative Disease Drugs

ATC Classification

N06DX01 - memantine ; Belongs to the class of other anti-dementia drugs.

Regulatory Classification

Presentation/Packing

Form

Cimantin FC tab 10 mg

Packing/Price

2 × 14's

Cimantin

memantine

Manufacturer:

Yarindo Farmatama